A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide ISA-51 in Patients With Cancer Expressing NY-ESO-1 or LAGE-1
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Cancer vaccine NY-ESO-1 (Primary) ; Cancer vaccine NY-ESO-1 (Primary) ; Agatolimod; Montanide ISA-51
- Indications Non-small cell lung cancer; Oesophageal cancer
- Focus Adverse reactions; Pharmacodynamics
- 24 Mar 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 28 Aug 2006 Status change
- 19 Dec 2005 New trial record.